|MDACC Study No:||2011-1165 (clinicaltrials.gov NCT No: NCT01590082)|
|Title:||Phase I / II Study of the Combination of Doxycycline with Temozolomide and Ipilimumab in patients with Metastatic Melanoma|
|Principal Investigator:||Kevin B. Kim|
|Treatment Agent:||Doxycycline; Ipilimumab; Temozolomide|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of doxycycline that can be combined with temozolomide and ipilimumab in
patients with advanced melanoma. The safety and level of effectiveness of the
study drug combination will also be studied.
Doxycycline is designed to treat bacterial infection. It also blocks a protein
called iNOS that is important in tumor cell growth, which may slow the growth
of or kill cancer cells.
Temozolomide is designed to stop cancer cells from making new DNA (the genetic
material of cells). This may stop the cancer cells from dividing into new
Ipilimumab is designed to block the activity of cells that decrease the immune
system's ability to fight cancer.